XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration and License Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2016
target
Mar. 31, 2023
USD ($)
obligation
Mar. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Aug. 31, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License related revenue   $ 0 $ 30,000,000    
GSK Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Contract with customer, expiration period   10 years      
Number of performance obligations | obligation   3      
Transaction price   $ 90,286,000      
GSK Agreement | License          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License related revenue   0 30,000,000    
GSK Agreement | License | Transferred at Point in Time          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payment         $ 85,000,000
License related revenue       $ 85,000,000  
GSK Agreement | License | Transferred over Time          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Additional payments to be received   4,524,000     4,314,000
GSK Agreement | Transition Services | Transferred over Time          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Additional payments to be received   762,000     $ 950,000
GSK Agreement | Clinical Milestone Payment          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential milestones payment   60,000,000      
GSK Agreement | Regulatory Milestone Payment          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential milestones payment   155,000,000      
GSK Agreement | Sales Milestone Payment          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential milestones payment   485,000,000      
Novartis Collaboration          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of option targets | target 4        
Number of option targets purchased | target 3        
Upfront, milestone, and option purchase payments, aggregate amount   150,000,000      
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue   0 $ 0    
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc. | Development Milestone          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential milestones payment   325,000,000      
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc. | Sales Milestone          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential milestones payment   $ 200,000,000